We examined NID1 expression using RNA sequencing data from pediatric patients with AML (n = associated significantly with worse EFS (p = 0.01) in this cohort (Figure 1B), as corroborated by multivariate Cox regression results [EFS: HR 1.321, 90% CI 1.071–1.631, p = 0.029; Figure 1C]. This evidence concerns the gene NID1 and acute myeloid leukemia.